Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SORD | Q00796 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20952436 | 0.84 | TSHR (0.72) | TSHRALDH1A1RAB9ASMN1; SMN2POLB | |
| SCHEMBL8437512 | 0.81 | TSHR (1.00) | TSHRALDH1A1RAB9ASMN1; SMN2POLB | |
| SCHEMBL27596185 | 0.76 | ALDH1A1 (0.68) | TSHRALDH1A1RAB9ASMN1; SMN2POLB | |
| SCHEMBL30896612 | 0.73 | TSHR (0.61) | TSHRALDH1A1RAB9ASMN1; SMN2POLB | |
| SCHEMBL30896611 | 0.73 | TSHR (0.61) | TSHRALDH1A1RAB9ASMN1; SMN2POLB | |
| SCHEMBL10469851 | 0.72 | SMN1; SMN2 (0.67) | TSHRALDH1A1RAB9ASMN1; SMN2POLB | |
| SCHEMBL10471423 | 0.71 | SMN1; SMN2 (0.65) | TSHRALDH1A1RAB9ASMN1; SMN2POLB | |
| SCHEMBL30896637 | 0.71 | GAA (0.65) | TSHRALDH1A1RAB9ASMN1; SMN2POLB | |
| SCHEMBL11279898 | 0.69 | DRD2 (0.54) | TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL3578337 | 0.68 | TSHR (0.51) | TSHRALDH1A1RAB9ASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772236-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7589202-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20080300255-A1 | Substituted pyrazoles | BEAVERS MARY PAT | 2008-12-04 | — | — | US | disclosed |
| US-20080293732-A1 | Substituted pyrazoles | BEAVERS MARY PAT | 2008-11-27 | — | — | US | disclosed |
| US-7452890-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7429591-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7417046-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7393850-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7388011-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-7332494-B2 | Method for treating allergies using substituted pyrazoles | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-02-19 | — | — | US | disclosed |
| WO-2002014314-A2 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| US-6284775-B1 | PSYCHOLOGICAL DISORDERS | AVENTIS PHARMACEUTICALS INC. | 2001-09-04 | — | — | US | disclosed |
| US-5801186-A | ANTIPSYCHOTIC AGENTS | HOECHST MARION ROUSSEL, INC. (US) | 1998-09-01 | — | — | US | disclosed |
| US-5371087-A | Antipsychotic, analgesics, anticonvulsant and anxiolytic agent | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1994-12-06 | — | — | US | disclosed |
| EP-0625978-A1 | PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-11-30 | — | — | EP | disclosed |
| WO-1993016073-A1 | PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-19 | — | — | WO | disclosed |
| US-5229388-A | 3-[4-(1-substituted-4-piperazinyl)butyl]-4-thiazolidinone and related compounds | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-07-20 | — | — | US | disclosed |
| US-5136037-A | 3-(4-substituted-4-piperazinyl)butyl-4-thiazolidinone and related compounds | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1992-08-04 | — | — | US | disclosed |
| US-5037984-A | Anticonvulsants; anxiolytic agents | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1991-08-06 | — | — | US | disclosed |
| US-4933453-A | ANTIPSYCHOTIC, ANALGESIC, ANTICONVULSANT, AND ANXIOLYTIC AGENTS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1990-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293732-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSB | TSHR 2804/4885ALDH1A1 2453/4885RAB9A 673/4885 |
| US-20080300255-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSB | TSHR 2804/4885ALDH1A1 2453/4885RAB9A 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.